Paratek Pharmaceuticals Inc  

(Public, NASDAQ:PRTK)   Watch this stock  
Find more results for NASDAQ:TSPT
-0.64 (-3.20%)
Real-time:   10:38AM EST
NASDAQ real-time data - Disclaimer
Currency in USD
Range 19.17 - 19.98
52 week 16.00 - 45.96
Open 19.98
Vol / Avg. 5,735.00/17,511.00
Mkt cap 278.99M
P/E     -
Div/yield 8.01
EPS -12.55
Shares 1.60M
Beta     -
Inst. own 69%
Nov 28, 2014
Q3 2014 Transcept Pharmaceuticals Inc Earnings Release (Estimated)
Oct 28, 2014
Transcept Pharmaceuticals Inc Extraordinary Shareholders Meeting
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin -4506.04% -1571.04%
Operating margin -4486.81% -1566.74%
EBITD margin - -1374.30%
Return on average assets -81.01% -31.96%
Return on average equity -86.47% -32.84%
Employees 8 -
CDP Score - -


75 Kneeland St Fl 6
BOSTON, MA 02111-1901
United States - Map
+1-617-2750040 (Phone)
+1-617-2750039 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Paratek Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of products that address therapeutic needs in the field of neuroscience. In November 2011, the United States Food and Drug Administration (FDA) approved its new drug application (NDA) for Intermezzo (zolpidem tartrate) sublingual tablet C-IV for use as needed for the treatment of insomnia when a middle-of-the-night awakening is followed by difficulty returning to sleep. In March 2011, the Company began a Phase II study of TO-2061, a low dose of ondansetron adjunctive treatment for patients with obsessive compulsive disorder (OCD), who has not adequately responded to first-line therapy.

Officers and directors

Michael F. Bigham CPA Chairman of the Board, Chief Executive Officer
Age: 55
Bio & Compensation  - Reuters
Evan Loh M.D. President, Chief Medical Officer
Age: 55
Bio & Compensation  - Reuters
Kathryn M. Boxmeyer Interim Chief Financial Officer, Director
Age: 39
Bio & Compensation  - Reuters
Frederick J. Ruegsegger Independent Director
Age: 58
Bio & Compensation  - Reuters